title: [A Patient with Lung Adenocarcinoma, Lymphangitis Carcinomatosa, and Multiple Bone Metastases Who Achieved Long-Term Survival after Successful Treatment with Carboplatin, Paclitaxel, and Bevacizumab].
abstract: BACKGROUND
  Lymphangitis carcinomatosa of the lung is intractable and associated with a poor prognosis.
  
  
  METHODS
  A 53-year-old woman was admitted to our hospital due to an uncomfortable feeling on deep inspiration. She was diagnosed with left lung adenocarcinoma with lymphangitis carcinomatosa and bone metastases to the frontal bone of the skull and thoracic vertebrae. The lung carcinoma was positive for an EGFR mutation. Because the patient's performance status (PS) was 0, carboplatin plus paclitaxel plus bevacizumab therapy was initiated and she received zoledronic acid and concurrent radiation therapy of 40 Gy for the metastasis to the thoracic vertebrae. After 2 courses of treatment, the respiratory symptoms had improved. After 6 courses of treatment, a chest CT indicated that the lymphangitis carcinomatosa had disappeared. The serum CEA level, which was 126.2 ng/mL (normal<5.0) before treatment, reduced to 5.0 ng/mL. She was administered 10 courses of bevacizumab as a maintenance therapy; however, the CEA level rose again to 11.7 ng/mL, the lung tumor volume increased, and the metastasis of the frontal bone deteriorated. As second-line chemotherapy, EGFR-TKI was started. However, after 11 months, because of grade 4 liver dysfunction, EGFR-TKI was stopped. She then received fourth-line chemotherapy in our outpatient hospital. This patient has survived 52 months since the initial diagnosis.
  
  
  CONCLUSIONS
  Chemotherapy including bevacizumab facilitated long-term survival (52 months) of a patient with lung adenocarcinoma accompanied by lymphangitis carcinomatosa and multiple bone metastases.
authors.affiliation: Division of Thoracic Surgery, Respiratory Disease Center, Seirei Mikatahara General Hospital.
authors.forename: Eriko
authors.initials: E
authors.lastname: Suzuki
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tanahashi
authors.forename: Haruhiro
authors.initials: H
authors.lastname: Yukiue
authors.forename: Naoko
authors.initials: N
authors.lastname: Yoshii
authors.forename: Masayuki
authors.initials: M
authors.lastname: Shitara
authors.forename: Toshio
authors.initials: T
authors.lastname: Fujino
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Niwa
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000077192:Adenocarcinoma of Lung; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D016190:Carboplatin / Q000008:administration & dosage; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000628:therapy*; D008205:Lymphangitis / Q000209:etiology*; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D013997:Time Factors
chemical_list: D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel